nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2014 | Original Article

Prospective evaluation of ⁶⁸Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative ¹³¹I-whole body scan: comparison with ¹⁸F-FDG PET-CT

verfasst von: Parveen Kundu, Sneh Lata, Punit Sharma, Harmandeep Singh, Arun Malhotra, Chandrasekhar Bal

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the study was to evaluate the role of ⁶⁸Ga-DOTANOC PET-CT in differentiated thyroid cancer (DTC) patients with negative ¹³¹I-whole body scan (WBS) along with serially increasing serum thyroglobulin (Tg), and compare the same with ¹⁸F-FDG PET-CT.

Methods

Sixty two DTC patients with serially rising Tg levels and negative ¹³¹I-WBS were prospectively enrolled. All patients underwent ⁶⁸Ga-DOTANOC PET-CT and ¹⁸F-FDG PET-CT within an interval of two weeks. PET-CT analysis was done on a per-patient basis, location wise and lesion wise. All PET-CT lesions were divided into four categories-local, nodal, pulmonary and skeletal. Histopathology and/or serial serum Tg level, clinical and imaging follow up (minimum-1 year) were used as a reference standard.

Results

Ga-DOTANOC PET-CT demonstrated disease in 40/62 (65 %) patients and ¹⁸F-FDG PET-CT in 45/62 (72 %) patients, with no significant difference on McNemar analysis (p = 0.226). Per-patient sensitivity and specificity of ⁶⁸Ga-DOTANOC PET-CT was 78.4 %, 100 %, and for ¹⁸F-FDG PET-CT was 86.3 %, 90.9 %, respectively. Out of 186 lesions detected by both PET-CTs, 121/186 (65 %) lesions were seen on ⁶⁸Ga-DOTANOC PET-CT and 168/186 (90.3 %) lesions on ¹⁸F-FDG PET-CT (p < 0.0001). There were 103/186 (55 %) lesions concordant on both. Excellent agreement was noted between ⁶⁸Ga-DOTANOC PET-CT and ¹⁸F-FDG PET-CT for detection of local disease (ĸ = 0.92), while moderate agreement was noted for nodal and pulmonary disease (ĸ = 0.67). ⁶⁸Ga-DOTANOC PET-CT changed management in 21/62 (34 %) patients and ¹⁸F-FDG PET-CT in 17/62 (27 %) patients.

Conclusion

Ga-DOTANOC PET-CT is inferior to ¹⁸F-FDG PET-CT on lesion based but not on patient based analysis for detection of recurrent/residual disease in DTC patients with negative WBS scan and elevated serum Tg levels. It can also help in selection of potential candidates for peptide receptor radionuclide therapy.

Menendez Torre E, Lopez Carballo MT, Rodriguez Erdozain RM, et al. Prognostic value of thyroglobulin serum levels and 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid. 2004;14:301–6.PubMedCrossRef

Preissner CM, O’Kane DJ, Singh RJ, et al. Phantoms in the assay tube:heterophile antibody interference in serum thyroglobulin assays. J Clin Endocrinol Metab. 2003;88:3069–74.PubMedCrossRef

Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46:1473–80.PubMed

Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–45.PubMedCrossRef

Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007;148:948–53.PubMedCrossRef

Min JJ, Chung JK, Lee YJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45.CrossRef

Krishna L, Dadparvar S, Brady LW, et al. Paradoxical changes in iodine-131 scintigraphic findings in advanced follicular thyroid cancer. J Nucl Med. 1993;34:1574–6.PubMed

Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547–52.PubMedCrossRef

Luong QT, O’Kelly J, Braunstein GD, et al. Antitumor activity of suberoylanilidehydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.PubMedCrossRef

10.

Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.PubMedCrossRef

11.

Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab. 2000;85:2889–96.PubMed

12.

Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med. 2005;46:107S–14.PubMed

13.

Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res. 2010;42:237–40.PubMedCrossRef

14.

Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res. 2009;2:1–8.PubMedCentralPubMedCrossRef

15.

Sancak S, Hardt A, Singer J, et al. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves’ disease. Thyroid. 2010;20:505–11.PubMedCrossRef

16.

Pazaitou-Panayiotou K, Janson ET, Koletsa T, et al. Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones. 2012;11:290–6.PubMedCrossRef

17.

Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996;81:2541–4.PubMed

18.

Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F. Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. Eur J Endocrinol. 2004;150:277–83.PubMedCrossRef

19.

Stokkel MP, Verkooijen RB, Smit JW. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging. 2004;31:950–7.PubMedCrossRef

20.

Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.PubMedCrossRef

21.

Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high affiniy ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.PubMedCrossRef

22.

Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741–8.PubMedCrossRef

23.

Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76–83.PubMed

24.

Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.PubMedCrossRef

25.

Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.PubMedCrossRef

26.

Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol. 2008;15:286–92.PubMedCrossRef

27.

Dong M, Liu Z, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009;30:639–50.PubMedCrossRef

28.

Gabriel M, Froehlich F, Decristoforo C, et al. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31:330–41.PubMedCrossRef

29.

Rodrigues M, Traub-Weidinger T, Leimer M, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:1144–51.PubMedCrossRef

30.

Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006;91:3997–4000.PubMedCrossRef

31.

Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol. 2011;197:1221–38.PubMedCrossRef

32.

Basu S, Abhyankar A, Kand P, Kumar R, Asopa R, Rajan MG, et al. Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. Nucl Med Commun. 2011;32:654–8.PubMedCrossRef

Titel: Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT
verfasst von: Parveen Kundu
Sneh Lata
Punit Sharma
Harmandeep Singh
Arun Malhotra
Chandrasekhar Bal
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2723-9

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Early and delayed prediction of axillary lymph node neoadjuvant response by 18F-FDG PET/CT in patients with locally advanced breast cancer

From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a “new human species”?

The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers

11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects